Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Lipocine Inc. (LPCN)
|
Add to portfolio |
|
|
|
| Price: |
$1.48
| | Metrics |
| OS: |
5.32
|
M
| |
-42
|
% ROE
|
| Market cap: |
$7.87
|
M
| |
-58
|
% ROIC
|
|
Net cash:
|
$25.8
|
M
| |
$4.85
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($13.7)
|
M
| |
|
|
|
EBIT
|
($13.8)
|
M
| |
|
|
| EPS |
($0.77)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.5 | 16.1 | 24.8 | 0.2 | 0.4 | 0.0 | 0.0 | 18.6 |
| Revenue growth | -96.9% | -34.9% | 14928.9% | -61.5% | | | -100.0% | -9.9% |
| Cost of goods sold | -18.2 | -17.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 18.7 | 34.0 | 24.8 | 0.2 | 0.4 | 0.0 | 0.0 | 18.6 |
| Gross margin | 3743.9% | 210.9% | 100.0% | 100.0% | 100.0% | | | 100.0% |
| Research and development | 14.2 | 12.6 | 16.5 | 7.5 | 6.5 | 11.0 | 8.1 | 12.6 |
| General and administrative | 4.1 | 5.3 | 8.2 | 5.6 | 5.3 | 10.2 | 10.4 | 5.8 |
| EBIT | -12.1 | 3.1 | -18.0 | -12.9 | -11.3 | -21.2 | -18.5 | -18.4 |
| EBIT margin | -2423.9% | 19.5% | -72.6% | -7818.8% | -2646.0% | | | -99.1% |
| Pre-tax income | -10.8 | -0.6 | -21.0 | -13.0 | -11.7 | -21.0 | -19.0 | -18.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | | |
| Net income | -10.8 | -0.6 | -21.0 | -13.0 | -11.7 | -21.0 | -19.0 | -18.2 |
| Net margin | -2151.7% | -3.9% | -84.5% | -7883.7% | -2724.1% | | | -98.1% |
| |
| Diluted EPS | ($0.12) | ($0.01) | ($0.38) | ($0.50) | ($0.55) | ($1.05) | ($1.04) | ($1.11) |
| Shares outstanding (diluted) | 88.9 | 87.6 | 55.7 | 25.9 | 21.4 | 20.1 | 18.3 | 16.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|